Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 1,057 Shares

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,057 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares of the company’s stock, valued at approximately $5,029,300.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Paula Green also recently made the following trade(s):

• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total value of $13,941.18.

Twist Bioscience Trading Up 5.3 %

Shares of Twist Bioscience stock traded up $2.28 on Wednesday, hitting $45.42. The stock had a trading volume of 1,019,545 shares, compared to its average volume of 942,883. The company’s 50 day moving average price is $43.61 and its 200 day moving average price is $45.43. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -11.89 and a beta of 1.78. Twist Bioscience Co. has a 52-week low of $15.85 and a 52-week high of $60.90.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in TWST. Point72 Asset Management L.P. raised its stake in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares during the last quarter. Fred Alger Management LLC raised its stake in Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after acquiring an additional 575,080 shares during the last quarter. Victory Capital Management Inc. raised its stake in Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after acquiring an additional 300,891 shares during the last quarter. Farallon Capital Management LLC acquired a new position in Twist Bioscience during the 2nd quarter worth approximately $9,462,000. Finally, Driehaus Capital Management LLC increased its position in Twist Bioscience by 63.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after purchasing an additional 150,260 shares during the period.

Analyst Ratings Changes

A number of research firms recently issued reports on TWST. Barclays decreased their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird lifted their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Finally, Evercore ISI raised their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.